These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23360802)

  • 1. Modeling dyskinesia in animal models of Parkinson disease.
    Morin N; Jourdain VA; Di Paolo T
    Exp Neurol; 2014 Jun; 256():105-16. PubMed ID: 23360802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of L-DOPA-induced dyskinesia: an update on the current options.
    Iderberg H; Francardo V; Pioli EY
    Neuroscience; 2012 Jun; 211():13-27. PubMed ID: 22465440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
    Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
    Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-human primate models of PD to test novel therapies.
    Morissette M; Di Paolo T
    J Neural Transm (Vienna); 2018 Mar; 125(3):291-324. PubMed ID: 28391443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
    Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
    Smith CP; Oh JD; Bibbiani F; Collins MA; Avila I; Chase TN
    Neuropharmacology; 2007 Feb; 52(2):515-26. PubMed ID: 17116309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.
    Johnston TH; Huot P; Fox SH; Koprich JB; Szeliga KT; James JW; Graef JD; Letchworth SR; Jordan KG; Hill MP; Brotchie JM
    Neuropharmacology; 2013 Oct; 73():337-47. PubMed ID: 23770260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
    Chen X; Wang Y; Wu H; Cheng C; Le W
    Neurol Sci; 2020 Aug; 41(8):2055-2065. PubMed ID: 32185625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
    Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
    Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
    Koprich JB; Huot P; Fox SH; Jarvie K; Lang AE; Seeman P; Brotchie JM
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():151-6. PubMed ID: 23306217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
    Bourque M; Grégoire L; Di Paolo T
    Behav Brain Res; 2018 Jan; 337():183-185. PubMed ID: 28917506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the selective 5-HT
    Frouni I; Kwan C; Bédard D; Belliveau S; Bourgeois-Cayer É; Gaudette F; Beaudry F; Hamadjida A; Huot P
    Exp Brain Res; 2019 Jan; 237(1):29-36. PubMed ID: 30298296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.